Americas (WHO region) vs Zimbabwe: Hepatitis B surface antigen (HBsAg) prevalence (%)
Americas (WHO region)
0.0%
in 2024
Zimbabwe
1.8%
in 2024
Americas (WHO region) rank
12th
Zimbabwe rank
13th
Hepatitis B surface antigen (HBsAg) prevalence (%) over time
- Americas (WHO region)
- Zimbabwe
How they compare
Zimbabwe currently reports 1.8% against 0.0% in Americas (WHO region), a difference of 1.8%.
Across all 10 years both countries report, Zimbabwe has been ahead every year.
Americas (WHO region) ranks 12th and Zimbabwe ranks 13th of 13 groups.
Zimbabwe has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Americas (WHO region) | Zimbabwe | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.0% | 2.0% | 1.9% | Zimbabwe |
| 2020s | 0.0% | 2.0% | 2.0% | Zimbabwe |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hepatitis b surface antigen (hbsag) prevalence, Americas (WHO region) or Zimbabwe?
- Zimbabwe, at 1.8% against 0.0% in Americas (WHO region) as of 2024.
- What is the difference in hepatitis b surface antigen (hbsag) prevalence between Americas (WHO region) and Zimbabwe?
- 1.8%, with Zimbabwe ahead.
- How many years of comparable data are there for Americas (WHO region) and Zimbabwe?
- 10 years are reported by both, from 2015 to 2024.
- How do Americas (WHO region) and Zimbabwe rank globally for hepatitis b surface antigen (hbsag) prevalence?
- Americas (WHO region) ranks 12th and Zimbabwe ranks 13th of 13 groups.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hepatitis B surface antigen (HBsAg) prevalence (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.